Senior Postdoctoral Research Scientist
My research focuses on integration of global measures of RNA (transcriptomics) and protein (mass-spectrometry proteomics) in the post-mortem human brain to understand the molecular changes that leave us susceptible to neurodegeneration and identify biomarkers of disease progression. My current projects focus on:
1. Cerebrospinal fluid biomarkers of Alzheimer's Disease. In collaboration with colleagues at Massachusetts General Hospital and the Yale-NIDA Neuroproteomics Center, I am using data-independent mass-spectrometry to analyse the cerebrospinal fluid of 400 attendees of a neurology clinic, to identify Alzheimer's Disease specific protein signatures from individuals with varied neurological conditions
2. Neuropeptides and resilience to Alzheimer's Disease. In work funded by the Bright Focus Foundation, I am using non-tryptic mass-spectrometry to identify neuropeptides that are highly abundant in individuals who are resilient to amyloid and tau pathology, combined with work in human iPSC-derived neuronal cultures to ascertain if these peptides are actively protective of neuronal function.
3. Spatial proteomics in human post-mortem tissue. I am developing biochemical methods to fractionate human post-mortem brain tissue and mass-spectrometry to identify proteins that may change localisation in disease states.
Roadblock: improved annotations do not necessarily translate into new functional insights.
Hall NAL. et al, (2021), Genome Biol, 22
VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases
Quinn JP. et al, (2021), Brain Communications
Synaptic proteins associated with cognitive performance and neuropathology in older humans revealed by multiplexed fractionated proteomics
Carlyle BC. et al, (2021), Neurobiology of Aging, 105, 99 - 114
Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2.
Trombetta BA. et al, (2021), BMC Infect Dis, 21
Cerebrovascular Senescence Is Associated With Tau Pathology in Alzheimer’s Disease
Bryant AG. et al, (2020), Frontiers in Neurology, 11